keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer treatment

keyword
https://www.readbyqxmd.com/read/28454475/oridonin-induces-g2-m-cell-cycle-arrest-and-apoptosis-via-the-pi3k-akt-signaling-pathway-in-hormone-independent-prostate-cancer-cells
#1
Jianlei Lu, Xiang Chen, Shuang Qu, Bing Yao, Yuexin Xu, Jiahui Wu, Yucui Jin, Changyan Ma
Oridonin is an active constituent isolated from the traditional Chinese herb Rabdosia rubescens, which exerts antitumor effects in experimental and clinical settings. However, its antitumor effects and underlying mechanisms on prostate cancer cells have not yet been clearly identified. In the present study, the androgen-independent prostate cancer PC3 and DU145 cell lines were used as models to investigate the effects and possible mechanisms of oridonin on cellular proliferation and apoptosis. Results demonstrated that oridonin inhibited cellular proliferation, and was able to significantly induce G2/M cell cycle arrest and apoptosis...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454339/puma-decreases-the-growth-of-prostate-cancer-pc-3-cells-independent-of-p53
#2
Zhengfei Shan, Qingzuo Liu, Yuling Li, Jitao Wu, Dekang Sun, Zhenli Gao
PUMA (p53 upregulated modulator of apoptosis), a member of the B-cell lymphoma 2 (Bcl-2) protein family, is a pro-apoptotic protein. PUMA expression is modulated by the tumor suppressor p53. PUMA has a role in rapid cell death via p53-dependent and -independent mechanisms. To evaluate whether p53 is required for PUMA-mediated apoptosis in prostate cancer cells, p53 protein was silenced in human prostate cancer PC-3 cells by using p53 small interfering RNA (siRNA). The interference efficiency of p53 on RNA and protein levels was detected by reverse transcription-quantitative polymerase chain reaction and western blotting...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454190/evaluation-of-the-effect-of-epilobium-angustifolium-aqueous-extract-on-lncap-cell-proliferation-in-in-vitro-and-in-vivo-models
#3
Jakub P Piwowarski, Barbara Bobrowska-Korczak, Iwona Stanisławska, Wojciech Bielecki, Robert Wrzesien, Sebastian Granica, Katarzyna Krupa, Anna K Kiss
Epilobium sp. are commonly used in traditional medicine in the treatment of early stages of benign prostatic hyperplasia and inflammation. It is suggested that a dominating constituent, oenothein B, is responsible for the extracts therapeutic effects. Several bioactivities were established for extracts and oenothein B in various in vitro models, but due to the questionable bioavailability of this dimeric macrocyclic ellagitannin, their significance in the in vivo effects remains unresolved. We have thus focused our attention on a complex comparative investigation of the in vitro and in vivo activities of phytochemically characterized Epilobium angustifolium aqueous extract and oenothein B on prostate cancer cells proliferation...
April 28, 2017: Planta Medica
https://www.readbyqxmd.com/read/28453701/an-exploratory-analysis-of-alkaline-phosphatase-lactate-dehydrogenase-and-prostate-specific-antigen-dynamics-in-the-phase-3-alsympca-trial-with-radium-223
#4
O Sartor, R E Coleman, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan, N J Vogelzang, Ø Bruland, S Kobina, S Wilhelm, L Xu, M Shan, M W Kattan, C Parker
Background: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not established. Patients and methods: The radium-223 ALSYMPCA trial enrolled patients with CRPC and symptomatic bone metastases. Prognostic potential of baseline variables was assessed using Cox models. Percentage changes in biomarker levels from baseline were evaluated during the trial period; changes from baseline to week 12 were evaluated for association with OS and surrogacy...
May 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28449236/discovery-of-lhrh-and-development-of-lhrh-analogs-for-prostate-cancer-treatment
#5
Andrew V Schally, Norman L Block, Ferenc G Rick
The discovery, isolation, elucidation of structure, synthesis, and initial testing of the neuropeptide hypothalamic luteinizing hormone-releasing hormone (LHRH), which regulates reproduction, is briefly described. The design, synthesis, and experimental and clinical testing of agonistic analogs of LHRH is extensively reviewed focusing on the development of new methods for the treatment of prostate cancer. Subsequent development of antagonistic analogs of LHRH is then faithfully recounted with special emphasis on therapy of prostate cancer and BPH...
April 27, 2017: Prostate
https://www.readbyqxmd.com/read/28449007/efficacy-of-stereotactic-body-radiotherapy-in-oligorecurrent-and-in-oligoprogressive-prostate-cancer-new-evidence-from-a-multicentric-study
#6
Luca Triggiani, Filippo Alongi, Michela Buglione, Beatrice Detti, Riccardo Santoni, Alessio Bruni, Ernesto Maranzano, Frank Lohr, Rolando D'Angelillo, Alessandro Magli, Alberto Bonetta, Rosario Mazzola, Nadia Pasinetti, Giulio Francolini, Gianluca Ingrosso, Fabio Trippa, Sergio Fersino, Paolo Borghetti, Paolo Ghirardelli, Stefano Maria Magrini
BACKGROUND: The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC). METHODS: Inclusion criteria of the present multicentre retrospective analysis were: (1) oligorecurrent PC, defined as the presence of 1-3 lesions (bone or nodes) detected with choline positron emission tomography or CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, defined as metastases (bone or nodes) detected after a prostatic-specific antigen rise during androgen deprivation therapy (ADT)...
April 27, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28447314/inhibition-of-the-insulin-like-growth-factor-1-receptor-potentiates-acute-effects-of-castration-in-a-rat-model-for-prostate-cancer-growth-in-bone
#7
Annika Nordstrand, Sofia Halin Bergström, Elin Thysell, Erik Bovinder-Ylitalo, Ulf H Lerner, Anders Widmark, Anders Bergh, Pernilla Wikström
Prostate cancer (PCa) patients with bone metastases are primarily treated with androgen deprivation therapy (ADT). Less pronounced ADT effects are seen in metastases than in primary tumors. To test if acute effects of ADT was enhanced by concurrent inhibition of pro-survival insulin-like growth factor 1 (IGF-1), rats were inoculated with Dunning R3327-G tumor cells into the tibial bone marrow cavity and established tumors were treated with castration in combination with IGF-1 receptor (IGF-1R) inhibitor NVP-AEW541, or by each treatment alone...
April 26, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28446934/endoscopic-extraperitoneal-radical-prostatectomy-after-radical-resection-of-pt1-pt2-rectal-cancer-a-report-of-thirty-cases
#8
Zhuo Liu, Dechuan Li, Yinbo Chen
INTRODUCTION: Endoscopic extraperitoneal radical prostatectomy (EERPE) has gained popularity for the treatment of localized prostate cancer. However, prior complex lower abdominal or pelvic surgery can complicate subsequent EERPE. To date, there have been few reports on patients who underwent EERPE after radical resection of pT1-pT2 rectal cancer. AIM: To present our experience with EERPE in patients after radical resection of pT1-pT2 rectal carcinoma and introduce a simple and effective way to create an extraperitoneal working space...
2017: Wideochirurgia i Inne Techniki Mało Inwazyjne, Videosurgery and Other Miniinvasive Techniques
https://www.readbyqxmd.com/read/28446540/human-prostate-luminal-cell-differentiation-requires-notch3-induction-by-p38-mapk-and-myc
#9
Sander B Frank, Penny L Berger, Mats Ljungman, Cindy K Miranti
Many pathways dysregulated in prostate cancer are also involved in epithelial differentiation. To better understand prostate tumor initiation, we sought to investigate specific genes and mechanisms required for normal basal to luminal cell differentiation. Utilizing human prostate basal epithelial cells and an in vitro differentiation model, we tested the hypothesis that p38-MAPK regulation of NOTCH3, via MYC, is required for luminal differentiation. Inhibition (SB202190, BIRB796) or knockdown of p38α and/or p38δ prevented proper differentiation...
April 26, 2017: Journal of Cell Science
https://www.readbyqxmd.com/read/28445962/psma-homing-dsrna-chimeric-protein-vector-kills-prostate-cancer-cells-and-activates-anti-tumor-bystander-responses
#10
Yael Langut, Nufar Edinger, Efrat Flashner-Abramson, Naomi Melamed-Book, Mario Lebendiker, Yael Levi-Kalisman, Shoshana Klein, Alexander Levitzki
The treatment of metastatic androgen-resistant prostate cancer remains a challenge. We describe a protein vector that selectively delivers synthetic dsRNA, polyinosinic/polycytidylic acid (polyIC), to prostate tumors by targeting prostate specific membrane antigen (PSMA), which is overexpressed on the surface of prostate cancer cells.The chimeric protein is built from the double stranded RNA (dsRNA) binding domain of PKR tethered to a single chain anti-PSMA antibody. When complexed with polyIC, the chimera demonstrates selective and efficient killing of prostate cancer cells...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445277/cancer-studies-based-on-secondary-data-analysis-of-the-taiwan-s-national-health-insurance-research-database-a-computational-text-analysis-and-visualization-study
#11
Jui-Kun Chiang, Chih-Wen Lin, Chun-Lung Wang, Malcolm Koo, Yee-Hsin Kao
There has been a surge in the academic publication output based on secondary analyses of the data from the Taiwan's National Health Insurance claim records. It has become a challenge to comprehend such a rapid expansion of the literature. Therefore, this study aimed to explore the conceptual content of National Health Insurance Research Database-based cancer research, using the abstract of articles extracted from PubMed between 2002 and 2015. Search terms including "National Health Insurance Research Database (NHIRD) AND Taiwan," "Taiwan AND population-based," and "Taiwan AND nationwide" were used to search in PubMed with the publication date limited to between 1997 and 2015...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28445167/spatial-features-of-dose-surface-maps-from-deformably-registered-plans-correlate-with-late-gastrointestinal-complications
#12
Calyn R Moulton, Michael J House, Victoria Lye, Colin I Tang, Michele Krawiec, David J Joseph, James W Denham, Martin A Ebert
This study investigates the associations between spatial distribution of dose to the rectal surface and observed gastrointestinal toxicities after deformably registering each phase of a combined external beam radiotherapy (EBRT)/high-dose-rate brachytherapy (HDRBT) prostate cancer treatment. The study contains data for 118 patients where the HDRBT CT was deformably-registered to the EBRT CT. The EBRT and registered HDRBT TG43 dose distributions in a reference 2 Gy/fraction were 3D-summed. Rectum dose-surface maps (DSMs) were obtained by virtually unfolding the rectum surface slice-by-slice...
April 26, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28445145/influence-of-serum-cholesterol-level-and-statin-treatment-on-prostate-cancer-aggressiveness
#13
Thomas J Schnoeller, Florian Jentzmik, Andres J Schrader, Julie Steinestel
Both cholesterol levels and the use of statins have been described to influence the development and prognosis of prostate cancer (PC). In this retrospective, cross-sectional analysis of consecutive cases from a tertiary referral center we evaluated an association between hypercholesterolemia (≥5.0mmol/l), the use of statins, and advanced/aggressive PC in 767 men with histologically confirmed, clinically localized PC awaiting radical prostatectomy. We found that patients with HCE (n=287, 37.4%) had a significantly higher incidence of poorly differentiated PC (Gleason score ≥7b, 81...
April 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28444831/analysis-of-modulation-factor-to-shorten-the-delivery-time-in-helical-tomotherapy
#14
Hidetoshi Shimizu, Koji Sasaki, Hiroyuki Tachibana, Natsuo Tomita, Chiyoko Makita, Kuniyasu Nakashima, Kazushi Yokoi, Takashi Kubota, Manabu Yoshimoto, Tohru Iwata, Takeshi Kodaira
A low modulation factor (MF) maintaining a good dose distribution contributes to the shortening of the delivery time and efficiency of the treatment plan in helical tomotherapy. The purpose of this study was to reduce the delivery time using initial values and the upper limit values of MF. First, patients with head and neck cancer (293 cases) or prostate cancer (181 cases) treated between June 2011 and July 2015 were included in the analysis of MF values. The initial MF value (MFinitial ) was defined as the average MFactual value, and the upper limit of the MF value (MFUL ) was defined according the following equation: MFUL = 2 × standard deviation of MFactual value + the average MFactual Next, a treatment plan was designed for patients with head and neck cancer (62 cases) and prostate cancer (13 cases) treated between December 2015 and June 2016...
April 26, 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28444552/income-and-health-related-quality-of-life-among-prostate-cancer-patients-over-a-one-year-period-after-radical-prostatectomy-a-linear-mixed-model-analysis
#15
Jens Klein, Daniel Lüdecke, Kerstin Hofreuter-Gätgens, Margit Fisch, Markus Graefen, Olaf von dem Knesebeck
PURPOSE: To examine income-related disparities in health-related quality of life (HRQOL) over a one-year period after surgery (radical prostatectomy) and its contributory factors in a longitudinal perspective. Evidence of associations between income and HRQOL among patients with prostate cancer (PCa) is sparse and their explanations still remain unclear. METHODS: 246 males of two German hospitals filled out a questionnaire at the time of acute treatment, 6 and 12 months later...
April 25, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28444169/androgen-receptor-regulation-of-local-growth-hormone-in-prostate-cancer-cells
#16
M V Recouvreux, B Wu, A C Gao, S Zonis, V Chesnokova, N Bhowmick, L W Chung, S Melmed
Prostate cancer (PCa) growth is mainly driven by androgen receptor (AR), and tumors that initially respond to androgen deprivation therapy (ADT) or AR inhibition usually relapse into a more aggressive, castration resistant stage (CRPC). Circulating growth hormone (GH) has a permissive role in PCa development in animal models and in human PCa xenograft growth. As GH and GH receptor (GHR) are both expressed in PCa cells, we assessed whether prostatic GH production is linked to AR activity and whether GH contributes to the castration resistant phenotype...
April 21, 2017: Endocrinology
https://www.readbyqxmd.com/read/28443490/waiting-times-for-cancer-patients-in-sweden-a-nationwide-population-based-study
#17
Stephanie Robertson, Jan Adolfsson, Pär Stattin, Annika Sjövall, Rocio Winnersjö, Marianne Hanning, Kerstin Sandelin
AIMS: The reported long waiting times for cancer patients have mostly been related to prognostic outcome and less to patient-related experience to outcome. We assessed waiting times for patients with cancer of the breast, prostate, colon or rectum in Sweden. METHODS: The median time from referral to start of treatment was assessed using data from clinical cancer registers for patients who received curative treatment during 2011, 2012 and 2013. RESULTS: The median overall waiting time in different counties ranged from 7 to 28 days for breast cancer, from 117 to 280 days for prostate cancer, from 27 to 64 days for colon cancer and from 48 to 80 days for rectal cancer...
May 2017: Scandinavian Journal of Public Health
https://www.readbyqxmd.com/read/28443242/incidental-leydig-cell-tumor-in-patient-with-hormone-resistant-prostate-cancer
#18
M Sánchez Pérez, P Jiménez Marrero, D Kim Lee, M P Neumann, N Jorge Pérez, C Hernández Hernández, S Hernández Escobar, R Marrero Domínguez
We hereby present the case of a 55 years old patient with clinical diagnosis of high-risk prostate cancer T2bN1Mo Gleason 9 (4 + 5) treated with androgen deprivation therapy and external beam radiotherapy. Despite treatment, castration levels were not achieved and clinical progression was evidenced by the appearance of bone metastases and progression of PSA. After several hormonal treatments without any PSA or testosterone response, surgical castration was performed by bilateral orchiectomy. The pathology results showed an incidental Leydig cell tumor in the right testicle...
July 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28443145/initial-single-centre-canadian-experience-with-18f-fluoromethylcholine-positron-emission-tomography-computed-tomography-18f-fch-pet-ct-for-biochemical-recurrence-in-prostate-cancer-patients-initially-treated-with-curative-intent
#19
Simon Gauvin, Yannick Cerantola, Eléonore Haberer, Vincent Pelsser, Stephan Probst, Franck Bladou, Maurice Anidjar
INTRODUCTION: We sought to determine predictive factors (patient and prostate-specific antigen [PSA] characteristics) for 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) positivity in the context of biochemical recurrence after local treatment of prostate cancer (PCa) with curative intent. METHODS: This is a retrospective study including 60 18F-FCH PET/CT scans of patients with biochemical recurrence after initial radical prostatectomy (RP), external beam radiation therapy (EBRT), or focal high-intensity focused ultrasound (HIFU) with curative intent...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28443142/effects-of-androgen-deprivation-therapy-on-hypercoagulability-in-prostate-cancer-patients-a-prospective-longitudinal-study
#20
Harmanpreet Kaur, D Robert Siemens, Angela Black, Sylvia Robb, Spencer Barr, Charles H Graham, Maha Othman
INTRODUCTION: Androgen-deprivation therapy (ADT) is the mainstay of systemic therapy for advanced prostate cancer (PCa), but has significant adverse effects, including increasing concern for cardiovascular (CV) and thromboembolic (TE) complications. This study carefully investigates any relationship between ADT use and hypercoagulability as a possible mechanism of these adverse effects. METHODS: We performed a prospective, longitudinal study in a cohort of patients with advanced PCa initiating ADT (n=18)...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
keyword
keyword
26059
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"